News

The trial results confirmed that single doses of up to 1,800mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300mg level achieved up to

The Ova1 test is intended to identify women with ovarian tumors that are at high risk of being malignant. Data from a 27-site, 511 subject prospective clinical trial

Under the terms of this agreement, sales of BiovaxID are expected to commence in the first calendar quarter of 2009, with the anticancer vaccine being made available to

On an intent-to-treat basis for the 125 enrolled patients, the median progression-free survival was 5.6 months on the Telcyta plus pegylated liposomal doxorubicin (PLD) arm compared to 3.7

Under the terms of the agreement, Theratechnologies will receive an upfront payment of $30 million which includes a license fee of $22 million and an equity investment of

ARC1905 represents one of three compounds that Ophthotech is developing to treat age-related macular degeneration (AMD). Additional molecular entities include E10030, an anti-PDGF aptamer currently in a Phase

Under the EU’s mutual recognition process, the company expects to receive renewal licenses for member states including Finland, Greece, Luxembourg, The Netherlands, Belgium, the UK and Portugal, over

Furthermore, the company announced that it will implement a strategic initiative to focus its resources on the clinical development of its proprietary pipeline. MethylGene will reacquire all rights

The Australian Patent Office has granted the company a patent that contains formulation and method claims to a pharmaceutical formulation comprising a macromolecular pharmaceutical agent in mixed micellar